Tumors present marked differences between patients, and between regions within single tumors. We analyze distinct tumor regions from clinical samples to associate between cancer proteomic heterogeneity, the tumor clinical parameters and the involvement of the tumor microenvironment. Through multi-region sampling of the tumors and their deep proteomic analyses, we achieve global mapping of tumor heterogeneity which is then translated to identification of novel cancer vulnerabilities.
Single cell proteomics aims to provide an unbiased functional characterization of cell populations in highly heterogeneous tumors. We develop novel mass spectrometry-based proteomic workflows to reach the necessary depth required to elucidate tumor cell interactions. We combine experimental and mass spectrometric method development to obtain deep proteome coverage, with high throughput sample preparation to provide robust sample preparation. Applications of this approach to cancer mouse models and to human tumors provides a unique view on cancer development and treatment resistance.
Molecular profiling of cancer has been performed primarily at the DNA and RNA levels. However, analyses of the protein level reflect more closely the cancer phenotype. By integrating proteomics with RNA-sequencing and with exome sequencing of the same samples, we investigate the contribution of each layer to the functional cellular phenotype. Multilayered tumor investigation provides the necessary perspective on cancer development and regulation.